{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:45:01Z","timestamp":1776879901953,"version":"3.51.2"},"reference-count":40,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCB, Tokyo, Japan, Japan"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate changes in oral corticosteroid (OCS) use after the publication of the 2014 Japanese clinical practice guidelines for myasthenia gravis (MG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study performed in three Japanese health insurance databases: the JMDC database between 2005 and 2021; the DeSC database covering the National Health Insurance (NHI) and the DeSC database covering the Late-Stage Elderly Healthcare Service (LSEHS) between 2014 and 2021. Achievement of OCS \u22645\u2009mg\/day was defined as \u226590 days of consecutive OCS \u22645\u2009mg\/day during follow-up, without any gap longer than 60 days between two consecutive claims. The time to achieve OCS \u22645\u2009mg\/day was estimated using Kaplan-Meier survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Real-world treatment setting in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients aged \u226516 years with a record of MG (International Classification of Diseases 10th edition code: G70.0) with a serological test, who had baseline period \u2265180 days before inclusion with no MG claim and who started immunotherapy (including OCS) within 90 days of MG diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Prescription of OCS and other therapies for MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 811 patients were included. The mean age was 49 years in the JMDC, 61 years in the NHI and 80 years in the LSEHS. In the JMDC, the median time to achieve OCS \u22645\u2009mg\/day was significantly shorter (p=0.042; log-rank test) in patients included in 2015 or later (11.0 months) than in patients included before 2015 (17.9 months). The median time to achieve OCS \u22645\u2009mg\/day was shorter in the LSEHS (6.5 months) than in the JMDC (11.0 months) and the NHI (11.7 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Faster tapering of the OCS dose was observed in patients starting treatment after the publication of the 2014 guidelines, although use of higher-dose OCS remained widespread after this date. This highlights the need to improve awareness of guidelines by healthcare providers in order to decrease the burden of higher-dose OCS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Clinical Trials Registry (UMIN-CTR): UMIN000051155; Post-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-095496","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T20:50:26Z","timestamp":1750625426000},"page":"e095496","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of 2014 Japanese practice guidelines on treatment patterns in patients with myasthenia gravis: an insurance claims database study"],"prefix":"10.1136","volume":"15","author":[{"given":"Shingo","family":"Konno","sequence":"first","affiliation":[{"name":"Department of Neurology, Toho University Ohashi Medical Center, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Samukawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kindai University Faculty of Medicine, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Todaka","sequence":"additional","affiliation":[{"name":"UCB, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Mishiro","sequence":"additional","affiliation":[{"name":"UCB, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Taki","sequence":"additional","affiliation":[{"name":"UCB, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Quelen","sequence":"additional","affiliation":[{"name":"Putnam, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrianna","family":"Czubin","sequence":"additional","affiliation":[{"name":"Putnam, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Majewska","sequence":"additional","affiliation":[{"name":"Putnam, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Shiraiwa","sequence":"additional","affiliation":[{"name":"UCB, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Ohashi","sequence":"additional","affiliation":[{"name":"UCB, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"2025121605085435000_15.6.e095496.1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025121605085435000_15.6.e095496.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274161","article-title":"Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018","volume":"17","author":"Yoshikawa","year":"2022","journal-title":"PLoS One"},{"key":"2025121605085435000_15.6.e095496.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.03.004"},{"key":"2025121605085435000_15.6.e095496.4","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"2025121605085435000_15.6.e095496.5","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"2025121605085435000_15.6.e095496.6","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/ene.14675","article-title":"Performance of different criteria for refractory myasthenia gravis","volume":"28","author":"Tran","year":"2021","journal-title":"Eur J Neurol"},{"key":"2025121605085435000_15.6.e095496.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126579","article-title":"Association between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional Study","volume":"10","author":"Konno","year":"2015","journal-title":"PLoS One"},{"key":"2025121605085435000_15.6.e095496.8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 Japanese version: validation and associations with clinical factors","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"key":"2025121605085435000_15.6.e095496.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000313","article-title":"Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study","volume":"1","author":"Suzuki","year":"2011","journal-title":"BMJ Open"},{"key":"2025121605085435000_15.6.e095496.10","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24213"},{"key":"2025121605085435000_15.6.e095496.11","unstructured":"Japanese Committee of Clinical Guidelines for Myasthenia Gravis . Japanese clinical guidelines for myasthenia gravis Tokyo: nankodo. 2014."},{"key":"2025121605085435000_15.6.e095496.12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology (ECronicon)"},{"key":"2025121605085435000_15.6.e095496.13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: Putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"2025121605085435000_15.6.e095496.14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"2025121605085435000_15.6.e095496.15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"2025121605085435000_15.6.e095496.16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330519"},{"key":"2025121605085435000_15.6.e095496.17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"2025121605085435000_15.6.e095496.18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cen3.12731","article-title":"Japan MG registry: Chronological surveys over 10 years","volume":"14","author":"Suzuki","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"2025121605085435000_15.6.e095496.19","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5680","article-title":"Inventory of real-world data sources in Japan: Annual survey conducted by the Japanese Society for Pharmacoepidemiology Task Force","volume":"33","author":"Kumamaru","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121605085435000_15.6.e095496.20","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2025121605085435000_15.6.e095496.21","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.11.1512"},{"key":"2025121605085435000_15.6.e095496.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-016-0756-3","article-title":"Response to treatment of myasthenia gravis according to clinical subtype","volume":"16","author":"Akaishi","year":"2016","journal-title":"BMC Neurol"},{"key":"2025121605085435000_15.6.e095496.23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.chest.2021.02.023","article-title":"Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort","volume":"160","author":"Alahmadi","year":"2021","journal-title":"Chest"},{"key":"2025121605085435000_15.6.e095496.24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.kint.2016.03.042","article-title":"Insights into the epidemiology and management of lupus nephritis from the US rheumatologist\u2019s perspective","volume":"90","author":"Hoover","year":"2016","journal-title":"Kidney Int"},{"key":"2025121605085435000_15.6.e095496.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200403-409OC"},{"key":"2025121605085435000_15.6.e095496.26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.33588\/rn.6601.2017436","article-title":"Adhesion al tratamiento farmacologico y descripcion de sus factores asociados en pacientes con miastenia grave [Pharmacological treatment compliance and a description of its associated factors in patients with myasthenia gravis].","volume":"66","author":"Idi\u00e1quez","year":"2018","journal-title":"Rev Neurol"},{"key":"2025121605085435000_15.6.e095496.27","doi-asserted-by":"crossref","unstructured":"Su Y , Wang X , Xing Y , et al . The analysis of factors affecting medication adherence in patients with myasthenia gravis: a cross-sectional study. Ther Adv Neurol Disord 2024;17. doi:10.1177\/17562864231206877","DOI":"10.1177\/17562864231206877"},{"key":"2025121605085435000_15.6.e095496.28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13760-019-01209-0","article-title":"Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study","volume":"120","author":"Vitturi","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"2025121605085435000_15.6.e095496.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2003.09.016"},{"key":"2025121605085435000_15.6.e095496.30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","article-title":"Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany","volume":"33","author":"Mevius","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"2025121605085435000_15.6.e095496.31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neurol.2023.09.004","article-title":"Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA)","volume":"180","author":"Salort-Campana","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"2025121605085435000_15.6.e095496.32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316625"},{"key":"2025121605085435000_15.6.e095496.33","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of Oral Steroid Therapy for Myasthenia Gravis","volume":"11","author":"Imai","year":"2020","journal-title":"Front Neurol"},{"key":"2025121605085435000_15.6.e095496.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011"},{"key":"2025121605085435000_15.6.e095496.35","first-page":"173","article-title":"Comparison of quality of life and activity of daily living status of patients with myasthenia gravis treated with low-dose and high-dose prednisolone","volume":"41","author":"Katsuki","year":"2020","journal-title":"Neuro Endocrinol Lett"},{"key":"2025121605085435000_15.6.e095496.36","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology (ECronicon)"},{"key":"2025121605085435000_15.6.e095496.37","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615"},{"key":"2025121605085435000_15.6.e095496.38","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15872"},{"key":"2025121605085435000_15.6.e095496.39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14712598.2023.2184257","article-title":"Biological therapies for myasthenia gravis","volume":"23","author":"Uzawa","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2025121605085435000_15.6.e095496.40","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1460"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-095496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:09:09Z","timestamp":1765890549000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-095496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,22]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-095496"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095496","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}